Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin for Aortic Valve Calcification in T2DM
NCT04521452Phase 4Unknown
- Sponsor
- Asan Medical Center
- Start
- Sep 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of DA5221-B2 in calcific aortic valve disease (CAVD), sponsored by Asan Medical Center. Status: unknown.
02
Drugs
DA5221-B2
03
Conditions
calcific aortic valve disease (CAVD)
Beyond the preview
Go deeper on NCT04521452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521452.